70 results about "Fat mouse" patented technology

The invention provides an application of alpha-mangostin for prevention and treatment of diabetes mellitus. Alpha-mangostin can be used for decreasing blood glucose of diabetics, increasing glucose tolerance and improving symptoms of polydipsia, polyuria, polyphagia, emaciation and thirsty of the diabetics, can also be used for lowering high-fat-diet-induced obesity mouse total cholesterol content, has a cholesterol lowering effect, is capable of improving abnormality of the high-fat-diet-induced mouse glucose tolerance, and has functions of preventing and delaying obese patients from getting diabetes mellitus.

An obese mouse model was developed by overexpressing the mitochondrial protein prohibitin (PHB) in white adipose tissue (WAT) specific manner driven by adipocyte protein 2 (aP2) promoter. These mice begin to develop obesity as a result of mitochondrial remodeling (upregulation of mitochondrial biogenesis and function) in WAT.

The invention discloses application of ampelopsin in preparing medicines for treating obesity, and relates to preparation and application of flavonoids compounds. The ampelopsin is used for preparing medicines or health products for treating the obesity, including oral tablets, capsules, granules, oral solution, sustained-release agents, pills and injection solution for treating the obesity, and pharmaceutically acceptable conventional formulations. The ampelopsin has obvious weight-losing effect on obese mice and overweight mice induced by high-fat diet; after the ampelopsin is poured into stomachs of the obese mice in a dose of 25.0mg / kg for 2 weeks, the abdominal fat is obviously reduced, shoulder fat cells are obviously shrunk, the weight is reduced to be normal, and the mice are generally good in conditions, freely acts and have smooth hairs. The maximum tolerance does of the mice through stomach perfusion can reach 18g / kg.

The invention discloses an application of soluble dietary fibers in kelp in preparation of lipid-lowering and weight-losing medicines and functional foods. The soluble dietary fibers are extracted from the waste kelp residues, after feeding for 3 weeks, the weight of obese mice is remarkably reduced compared with that of a negative control group; after 6 weeks of experiment period, the lipid-lowering effect is obvious; the epididymis fat and the liver of a mouse are subjected to histopathological section, the soluble dietary fibers in the section dyed by HE can obviously reduce the size of thefat, and the fat lesion of the liver of the mouse is relieved. By detecting mRNA expression of related factors related to lipid metabolism in fat and liver and mRNA expression of common inflammatoryfactors in obesity, the soluble dietary fibers can down-regulate expression of lipid synthesis genes and pro-inflammatory factors and up-regulate expression of lipid metabolism genes. The soluble dietary fiber disclosed by the invention is high in safety and low in price, and has a remarkable effect in the aspects of reducing fat and losing weight of OB obese mice.

The invention discloses a preparation method of large-leaf yellow tea polysaccharide with a blood sugar reducing effect. The preparation method is characterized in that large-leaf yellow tea polysaccharide LYT-2 is prepared by taking large-leaf yellow tea produced from Huoshan as a raw material, performing solid-state fermentation through EM bacteria and carrying out extracting by utilizing a deepeutectic solvent technology; the molecular weight of the polysaccharide compound is 4.38x104 Da, the polysaccharide compound contains 4.98% of binding protein, and the molar ratio of mannose to glucose to arabinose is 2.16:4.83:1 in monosaccharide composition. In-vivo experimental data shows that LYT-2 can obviously reduce the weight and blood sugar level of high-sugar and high-fat mice. The result shows that LYT-2 has good application prospects in the aspects of food, medicine, health care and the like.

The invention relates to an siRNA for inhibiting expression of an FABP4 gene. A sequence of the siRNA is shown as follows: sense strand: 5'-CGACCACAAUAAAGAGAAA-3' antisense strand: 5'-UUUCUCUUUAUUGUGGUCG-3'. According to the siRNA disclosed by the invention, three pairs of siRNA sequences are designed, aiming at the FABP4 gene, and an siRNA which is capable of effectively down regulating expression of a target gene is screened by virtue of a cell transfection test; according to the screened siRNA-368 sequence, a corresponding lentivirus expression carrier is constructed; and verified by a test of transfecting an obese mouse with high fat and inhibiting expression of mouse visceral fat tissue FABP4 gene, the screened siRNA is capable of effectively inhibiting expression of the mouse FABP4 gene and lowering weight, glycosylated hemoglobin, total cholesterol and level of low-density lipoprotein cholesterol of the obese mouse with high fat.

The invention designs a novel lipid-lowering polypeptide P48. The novel lipid-lowering polypeptide P48 is prolonged in a half-life period, plays the role of a GLP-1 receptor agonist and also plays therole of a GLP-1 analogue to adjust the fat content of an individual. The P48 peptide can be used for inhibiting feed intake of a non-alcoholic fatty liver model mouse induced by high-fat diet, remarkably reduce the weight of an obese mouse, lower the blood fat level of the obese mouse, maintain the normal form of the liver, inhibit liver cell injury, reduce accumulation of lipid in the liver andvacuolar deformation of cells, increase the level of adiponectin leptin in blood, and give a play to the blood glucose reducing and blood fat regulating effects of the adiponectin leptin; meanwhile, the P48 peptide obviously improves insulin tolerance and sugar tolerance. The novel lipid-lowering polypeptide P48 of the invention has potential pharmaceutical application in preparation of drugs fortreating and preventing obesity or complications thereof, namely non-alcoholic fatty liver diseases.

The invention relates to the technical field of food nutrition and in particular relates to application of sponge gourd powder in relieving branched-chain hyperaminoacidemia to inhibit obesity. To achieve the purpose, the invention provides a technical scheme of application of sponge gourd powder in relieving branched-chain hyperaminoacidemia to inhibit obesity. The application proves that the sponge gourd powder is capable of inhibiting obesity by reliving branched-chain hyperaminoacidemia. A preparation method of the sponge gourd powder comprises the following steps: cleaning and slicing sponge gourds, performing low-temperature freezing drying, and performing superfine grinding. By adopting the method, nutrient components of the sponge gourds can be maintained to the maximum extent. Results show that expression of a gene transcription level of a branched chain amino acid catabolism enzyme in adipose tissue and livers of fat mice can be increased, in-vivo branched chain amino acid catabolism can be promoted, branched-chain hyperaminoacidemia can be relieved, obesity and insulin resistance can be inhibited, and the sponge gourd powder can be used as a diet nutrition component forrelieving branched-chain hyperaminoacidemia to inhibit obesity.

The invention belongs to the technical field of Chinese traditional medicine application, and specifically relates to application of chrysin to preparation of drugs for treating obesity-related metabolically triggered inflammations. According to the invention, the chrysin promotes the replacement activation of IL-4 activated mouse macrophages, promotes the release of anti-inflammatory cytokines IL-10, and promotes the rise of enzyme activity of typical labeled molecule arginine for the replacement activation of the macrophages, the up-regulation of surface molecules MGL1 / 2 and the up-regulation of classical molecules CD206, Ym1 and Fizz. Especially, in fat mice C57 / B6 induced by high-fat feeding, the chrysin is capable of inhibiting the release of proinflammatory cytokines TNF-alpha, AST (Aspartate Transaminase) and ALT (Alanine Transferase) in blood serum, increasing the release of the anti-inflammatory cytokines IL-10, alleviating the lesion of liver and adipose tissues, inhibiting the phagocytic function of the peritoneal macrophages, the antigen presentation ability and the release ability of NO, and lowering the expression of the typically activated surface molecules CCR7 and CD80 of the macrophages. According to the invention, a new drug for treating the obesity-related metabolically triggered inflammations is developed.

The invention discloses an application of a brown adipocyte-derived exosome. The invention discloses application of the brown adipocyte-derived exosome in preparation of a medicine for treating non-alcoholic fatty liver, and preferably application in preparation of a medicine for treating non-alcoholic fatty liver caused by high fat obesity. The brown adipocyte-derived exosome is used for expressing symbolic proteins CD63, CD9 and TSG101. The extracted brown adipocyte-derived exosome can effectively reduce the weight of non-alcoholic fatty liver of high-fat-induced obese mice and the ratio of liver to volume, reduce the content of fatty acid and cholesterol in the liver, reduce the liver, slow down fat synthesis in the liver and increase the consumption of fatty acid at the same time. Therefore the invention provides a new way for treating non-alcoholic fatty liver of obese mice caused by high fat.

The invention discloses an application of spermidine in preparation of a preparation for improving the bacterial abundance of lachnospiraceae. The bacterial abundance of the lachnospiraceae NK4A136 group in the intestinal tract of an obese mouse can be remarkably improved by taking in exogenous spermidine, and the intestinal tract barrier function damage induced by metabolism related diseases suchas obesity is improved.

The invention discloses application of a fructan extract in preparing medicines, foods or health products for improving intestinal flora. The molecular weight of the fructan extract is 2000-10000. The fructan extract is prepared by the following steps: extracting Zhejiang ophiopogon root tuber with ethanol to remove impurities, extracting with water, carrying out ethanol fractional precipitation, and drying to obtain the fructan extract (the molecular weight is 2000-10000). The inspection on functions of the fructan extract by an abdomen-fat mouse model proves that the fructan extract has an obvious action of improving intestinal flora.

The invention discloses a function and application of a (pro) resin receptor [(pro) resin receptor, (P) RR] inhibitor in nonalcoholic fatty livers and fat diseases. Under the background of C57 mice, (P) RR liver specificity knock-out / know-down mice are used as experimental objects, according to a fat mouse model which is induced through high-fat feed, and it is proved through a result that the size of the liver (P) RR knock-out mice is remarkably small, and the fat tissue in the mouse bodies is remarkably reduced; after the mice are fed with the high-fat feed, the increase amplitude of the weight of the mice is low, fat is not generated, the blood glucose content is low, through results of oil red dyeing, liver lipid measurement and the like, it is explained that the liver function of theliver (pro) resin receptor knock-out mice is remarkably better than that of contrasted fatty mice, the fatty liver lesion of the mice is remarkably improved, the stored lipid is remarkably reduced, and the blood glucose content is lowered. Therefore, (P) RR can be used as a medicine target of screening treatment of type-II diabetes, nonalcoholic fatty livers and fat diseases, and the inhibitor of(P) RR can be applied to preparation of medicine for treating type-II diabetes, nonalcoholic fatty livers and fat diseases.

The invention provides an active component of peanut shells, which is obtained by leaching peanut shells with ethanol, suction filtration, concentration, separation with macroporous adsorption resin, and fraction collection. In anti-obesity and diabetes in vivo experiments, the present invention has confirmed that the active components of peanut coat can regulate adiponectin and leptin signaling pathways to reduce body weight and blood sugar through animal models of diabetes, and can significantly reduce experimental obesity mice and 2 The food intake, body weight and blood sugar level of type 2 diabetes model mice can significantly improve the clinical symptoms of obesity and diabetes. It can be used in the preparation of food, health food and medicine for preventing and treating obesity and diabetes.

The invention discloses a human secretory FNDC5 protein as well as a preparation method and application thereof, and relates to the technical field of gene engineering. The human secretory FNDC5 protein does not contain a transmembrane structural domain and can be directly secreted and released into blood. The human secretory FNDC5 protein can be used for preparing medicines for treating atherosclerosis, medicines for promoting bone formation and medicines for treating aplastic anemia, and can be used for preparing endothelial cell proliferation medicines. After fasting injection is conductedon a high-fat fed obese mouse model, the human secretory FNDC5 protein can effectively reduce the weight of an obese mouse, which shows that the protein can obviously improve body fat metabolism of anobese patient and obviously reduce the levels of plasma cholesterol, free fatty acid and triglyceride, and shows that the protein can obviously improve lipid metabolism disorder of the obese patient.

The invention discloses a function of tumor progress site 2 in treatment of fatty liver and type 2 diabetes as well as an application thereof. According to the invention, TPL2 gene knockout mice and wild type mice are taken as the experiment objects, through a high-fat diet-induced obesity mice model, the result shows that compared with the wild type C 57 mice, body weight of the TPL2 gene knockout mice is mitigated, the fasting blood glucose level is lower than that of a control group WT mice, and the hepatic dysfunction is obviously mitigated. Through intraperitoneal glucose tolerance experiment, the endurance of the TPL2 gene knockout mice on glucose is obviously enhanced. the mice liver tissue cholesterol content change result instructs that TPL2-KO mice fatty liver pathology of a HFD group (High fat diet) is obviously mitigated, and the lipid accumulation is obviously reduced. TPL2 can be taken as a drug target for treating fatty liver and / or type 2 diabetes, and its inhibitor can be used for preparing a drug to treating fatty liver and / or type 2 diabetes.

The invention provides an application of methyl myristoleate in preparation of products for preventing or treating metabolic syndromes or improving body energy metabolism, wherein the products are medicines, food or health products. A study indicates that methyl myristoleate (c14:1) can activate the thermogenic activity of brown fat (BAT) of hereditary obese db / db mice to consume excess body energy, thereby effectively improving the obesity of the hereditary obese db / db mice.

The invention discloses a function and application of SH3 domain-containing RING finger protein 2 (Sh3rf2) in preparing drugs for treating a non-alcoholic fatty liver disease and / or type-2 diabetes. According to the function and the application, Sh3rf2 gene knockout mice and wild type C57 mice are taken as experiment objects, through a fat mice model induced with high-fat and high-cholesterol (HFHC) diet, it is found that the weight of Sh3rf2 gene knockout mice increases in comparison with that of the wild type C57 mice in a control group; results of the liver weight, the liver / body weight, lipid composition pathological staining and the like all indicate that the Sh3rf2-KO mice in an HFHC group have obviously serious lesion of the fatty liver, and lipid accumulation increases; and the results show that Sh3rf2 gene knockout significantly worsens the progression of the non-alcoholic fatty liver disease. In allusion to the effect of the Sh3rf2, the Sh3rf2 can be used for preparing the drugs for preventing, alleviating and / or treating the nonalcoholic fatty liver disease and / or the type-2 diabetes.

The invention discloses a secretion-type FNDC5 protein. The secretion-type FNDC5 protein does not contain a transmembrane domain and can be directly secreted and released into blood; and the amino acid sequence of the FNDC5 protein is SEQ ID NO:1. The secretion-type FNDC5 protein is simple in structure and convenient to obtain. The secretion-type FNDC5 protein can be used for treating obesity-related metabolic disorders; after the secretion-type FNDC5 recombinant protein is injected into the abdominal cavity of a high-fat fed obese mouse model, glucose and insulin tolerance can be effectivelyimproved, and it shows that the protein can obviously relieve glucose metabolic disorders and insulin resistance of obese patients; and fatty liver occurrence can be obviously relieved, the level of plasma cholesterol, free fatty acid and triglyceride is decreased, and it shows that the protein can relieve the lipometabolic disorders of the obese patients. The secretion-type FNDC5 protein can serve as a new drug target for treating the metabolic disease to be developed.

The present invention relates to a novel Bifidobacterium longum or Lactobacillus rhamnosus strain having an effect of preventing or treating obesity, and a use thereof. Treatment of each of the lactic acid bacteria strains of Bifidobacterium longum and Lactobacillus rhamnosus, of the present invention, causes browning of white adipocytes and, particularly, it has been confirmed that beige adipocyte- and brown adipocyte-specific gene expression significantly increases over that of an untreated control group. In addition, as a result of experimentation on high fat diet-induced obese mice is carried out, each strain exhibits a weight gain inhibitory effect more significant than that of a negative control group, and an effect of increased expression of a thermogenesis-specific gene, in the white adipocytes of the mice, has been confirmed. Therefore, each of the lactic acid bacteria strains of Bifidobacterium longum and Lactobacillus rhamnosus exhibits an anti-obesity effect so as to be effectively usable as a food, a drug or a feed for preventing or treating obesity, thereby being very useful in related industries.

The invention discloses functions and application of an LILRB4 (leukocyte immunoglobulin-like receptor B4) gene to treatment on fatty liver diseases and diabetes. By taking LILRB4 gene knock-out mice and wide type C57 mice as experimental subjects and through high fat diet (HFD) induced obesity mouse models, result shows that compared with the wild type (WT) C57 mice, the weight of the LILRB4-KO mice is not remarkably changed after HFD, but the fasting blood-glucose level of the LILRB4-KO mice is higher than that of the WT mice in the control group and the liver function of the LILRB4-KO mice is remarkably worse than that of the WT mice. Intraperitoneal injection glucose tolerance experiments show that the glucose tolerance of the LILRB4-KO mice is remarkably weakened. The liver weight and liver / weight ratio, the lipid component pathological staining result and the like indicate that the fatty liver lesion of the LILRB4-KO mice in the HFD group is remarkably deteriorated and the lipid accumulation is remarkably increased. Therefore, the LILRB4 can serve as a target for screening medicines for treating the fatty liver and / or the type 2 diabetes mellitus, and an accelerant of the LILRB4 can be used for preparing the medicines for treating the fatty liver and / or the type 2 diabetes mellitus.

The invention provides an application of diethyl n-butylmalonate in preparation of medicines for preventing and treating obesity, and belongs to the technical field of biomedicines. Diethyl n-butylmalonate can reduce body weight and liver weight in obese mice, prevent lipid accumulation in liver tissues, enhance fatty acid oxidation in obese mice and increase energy consumption so as to achieve weight losing effect. Moreover, Diethyl n-butylmalonate can improve glucose tolerance and insulin resistance, and has the effect of correcting obesity-related metabolic disorders.

The invention relates to the technical field of microbial fermentation, in particular to a method for producing flavonoid substances by fermenting vegetable soybean off-grade goods with bacillus natto. The method comprises the following steps: selecting vegetable soybean off-grade goods; cleaning, sterilizing, steaming, fermenting by using bacillus natto, performing after-ripening to obtain a natto product, performing ultrasonic degreasing on freeze-dried fermented natto by using petroleum ether, performing heat reflux extraction on flavonoid substances in the natto by using an ethanol solution with a certain concentration, purifying a crude extract by using macroporous resin, spin-drying a collected solution, dissolving by using distilled water, and freeze-drying to obtain flavonoid powder. The flavonoid substances can be used as a lipid-lowering product, the purified flavonoid substances extracted from natto are used for gavage of high-fat mice, and the flavonoid substances are foundto be capable of lowering the blood lipid concentration in serum of the high-fat mice and improving the blood lipid metabolic clearance capacity and also have the health-care function of regulating immunity at the same time. The method has the characteristics of simple process, short flow and low cost, and is suitable for bean product processing enterprises with large, medium and small scales.

The invention discloses the function and application of three-structural-domain protein 8 in treating non-alcoholic fatty liver disease and II type diabetes mellitus. TRIM8 gene knockout mice and wild type C57 mice are used as experimental subjects, by means of a high-fat diet induced fat mice model, the result indicates that compared with the wild type C57 mice, the weight of the TRIM8 gene knockout mice is reduced, the fasting blood-glucose level of the TRIM8 gene knockout mice is lower than that of control group WT mice, and hepatosis is obviously relieved. Mouse liver weight, the liver / weight ratio and a lipid component pathological staining result show that fatty liver pathological changes of the TRIM8-KO mice having high-fat diet are obviously relieved, and lipid accumulation is remarkably reduced. Therefore, TRIM8 can serve as a drug target for screening and treating fatty liver disease and / or II type diabetes mellitus, and inhibitor of TRIM8 can be used for preparing a drug for treating fatty liver disease and / or II type diabetes mellitus.

The invention discloses an application of CGP 57380 in preparation of a medicine for preventing and treating type 2 diabetes. CGP 57380 is a cell-permeable pyrazole-pyrimidine compound, and it is found that CGP 57380 can relieve hyperglycemia and hyperinsulinemia of high-fat-induced type 2 diabetic mice and improve the glucose tolerance level and insulin sensitivity of high-fat mice by inhibiting the kinase activity and protein expression quantity of BRSK2, and finally, the glycolipid metabolism disorder of the high-fat mice is remarkably improved, the effect of treating the type 2 diabetes is achieved, and an important reference value is provided for clinical research and development of new drugs.

The invention relates to medical application of long-chain non-coding RNA (LncRNA-266), in particular to application of LncRNA-266 in preparation of a drug for inducing brown adipose cell differentiation, which can promote body energy consumption and resist obesity. Obese mice are treated by the LncRNA-266, and a result shows that the LncRNA-266 can promote differentiation of beige fat cells of the obese mice to brown fat cells and consume body energy, so that weight gain is inhibited. It is further found that the LncRNA-266 can reduce the blood glucose level of obese mice and improve the insulin sensitivity.

The invention relates to application of xanthan gum to the preparation of weight-reducing food and health-care food. The xanthan gum is microbial polysaccharide and has excellent high viscosity and water solubility and unique water-absorbing and swelling characteristic. The result of the experimental study on the animal shows that the xanthan gum can reduce the weight and the coefficient of the fat of the nutritional fat mice and has certain weight-reducing function. The xanthan gum is mixed with excipient by the conventional preparation process to be made into different types of weight-reducing food and health-care food, and the xanthan gum can be widely applied to the preparation of the weight-reducing food and the health-care food.

The invention discloses a fat reducing application of taro leaf polysaccharide. Taro leaf polysaccharide can be used to develop natural fat reducing products in the fields of medicine, food science, and the like. The experiment results show that taro leaf polysaccharide can obviously reduce the weight of fat mice, which have been induced by high fat diet, the contents of triglycerides and total cholesterol in the serum and liver are reduced, and the effect is comprehensive and obvious. Thus, taro leaf polysaccharide can be used to prepare fat reducing food or medicine, which can be used to treat and prevent obesity and related chronic diseases.

The invention relates to an application of dimethyl itaconate in the preparation of a medicine for treating and / or preventing obesity-induced intestinal micro ecological disorder. Experiments prove that dimethyl itaconate can correct intestinal micro ecological imbalance of obese mice, reduce intestinal inflammation and maintain intestinal barrier integrity.

The invention discloses a human-derived secreted FNDC5 protein and its preparation method and application, and relates to the technical field of genetic engineering; wherein the human-derived secreted FNDC5 protein does not contain a transmembrane domain, and can be directly secreted and released into blood; The human-derived secreted FNDC5 protein of the invention can be used for preparing medicines for treating atherosclerosis, promoting bone formation and treating aplastic anemia, and can prepare medicines for proliferation of endothelial cells. The human-derived secreted FNDC5 protein of the present invention can effectively reduce the body weight of obese mice after fasting injection to obese mouse models fed with high fat, indicating that the protein can significantly improve body fat metabolism of obese patients, significantly reduce plasma cholesterol, The levels of free fatty acids and triglycerides indicate that the protein can significantly improve lipid metabolism disorders in obese patients.